Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II)
Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II)
复制标题
DOI：
10.3892/etm.2010.123
复制
发表时间：
2010-09-01
影响因子：
2.7
通讯作者：
Nishioka, Akihito
中科院分区：
文献类型：
--
作者：
Hitomi, Jiro;Kubota, Kei;Nishioka, Akihito
新的酶靶向放射增敏治疗，Kochi Oxydol-放射治疗不可切除的癌症，II型（KORTUC II），显着提高了放射治疗对各种类型的局部晚期恶性肿瘤的效果。拒绝手术治疗和全身化疗的患者以及总共14名I期乳腺癌患者入选。在每次放射治疗给药前，在超声引导下每周两次将最多6 ml KORTUC II注射到肿瘤组织中。中位观察期为21.6个月，范围为4-48个月，治疗耐受性良好。对比增强磁共振成像和[F-18]-氟脱氧葡萄糖正电子发射计算机断层扫描显示，所有原发性乳腺肿瘤完全缓解，并且在观察期间没有受试者发生局部复发。2/14例治疗后超声显示瘤样改变。治疗前4/14例彩色多普勒血流信号阳性，治疗后全部消失。治疗后无血流信号表明超声检查的肿瘤样结果来自瘢痕组织。基于准确放射学评价的出色局部控制意味着KORTUC II有可能取代手术作为I期乳腺癌的治疗选择。通过各种放射学方式的精确评估有助于衡量这种治疗的成功。
The new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II), markedly enhances the radiotherapeutic effect of treatment for various types of locally advanced malignant neoplasms. Patients who had declined surgical treatment and systemic chemotherapy, as well as a total of 14 stage I breast cancer patients, were enrolled. A maximum of 6 ml of KORTUC II was injected into tumor tissue twice a week under ultrasonographic guidance, immediately prior to each administration of radiation therapy. The median observation period was 21.6 months with a range of 4-48 months, and the therapy was well tolerated. Contrast-enhanced magnetic resonance imaging and [F-18]-fluorodeoxyglucose positron emission computed tomography revealed that all primary breast tumors completely responded, and none of the subjects experienced local recurrence during the observation period. Ultrasonography depicted tumor-like findings in 2/14 cases after therapy. The intratumoral flow signal on color-Doppler sonography was positive in 4/14 cases before therapy, and the signal disappeared from all cases after therapy. The absence of a flow, signal after therapy suggested that the tumor-like findings on ultrasonography were from scar tissue. Excellent local control based on accurate radiological evaluation implies that KORTUC II has the potential to replace surgery as a therapeutic option for stage I breast cancer. Precise evaluation by various radiological modalities helped to gage the success of this therapy.